BioTuesdays

Tag - Nerlynx

Puma Biotechnology Logo

HCW starts Puma Biotechnology at buy; PT $15

H.C. Wainwright launched coverage of Puma Biotechnology (NASDAQ:PBYI) with a “buy” rating and $15 price target. The stock closed at $7.44 on Dec. 5. Puma has a marketed drug called Nerlynx, which was approved by the FDA...